Biotech News
GSK’s RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older
In the EU, an average of 158,000 adults are hospitalised with RSV-related illness every year
Related news
GSKGSK plc2026-08-24 07:00 EST
Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B
GSKGSK plc2026-08-24 07:01 EST
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
BNTXBioNTech2026-08-27 20:30 EST
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
IDYAIDEAYA Biosciences2026-08-31 10:00 EST
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
REGNRegeneron Pharmaceuticals2026-08-19 17:58 EST
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
REPLReplimune Group2026-08-06 20:00 EST
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
REPLReplimune Group2026-07-30 22:15 EST
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
RVMDRevolution Medicines2026-09-14 20:05 EST
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
COGTCogent Biosciences2026-09-15 12:00 EST
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-09-15 14:21 EST
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
GSKGSK plc2026-09-13 19:30 EST
GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer
GSKGSK plc2026-09-13 08:00 EST
Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China
GSKGSK plc2026-09-10 07:00 EST
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan
GSKGSK plc2026-09-01 07:00 EST
GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
Stock data
- Close
- 51.08 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States